Synthetic studies of neoclerodane diterpenes from Salvia divinorum: Exploration of the 1-position

https://doi.org/10.1016/j.bmcl.2007.09.050Get rights and content

Abstract

Modification of the C-1 ketone of salvinorin A (2a) produces analogues with opioid antagonist properties. Of particular significance is the finding that 1-deoxo-1,10-dehydrosalvinorin A (11a) is a moderately potent antagonist at all three opioid receptor subtypes, and that herkinorin (2b), a μ agonist, is converted to a weak antagonist by removal of the C-1 ketone (3b and 11b). These observations suggest that the ketone of 2b is a key structural feature responsible for μ agonist activity.

Section snippets

Acknowledgments

This work was supported by National Institutes of Health, National Institute on Drug Abuse Grant DA018151 (to T.E.P.). The authors also thank Keith Warner for technical assistance and the American Foundation for Pharmaceutical Education (K.T.) and the University of Iowa Graduate College (A.M.) for predoctoral fellowships.

References and notes (28)

  • C. Beguin et al.

    Bioorg. Med. Chem. Lett.

    (2006)
  • R.V. Bikbulatov et al.

    Bioorg. Med. Chem. Lett.

    (2007)
  • W.W. Harding et al.

    Bioorg. Med. Chem. Lett.

    (2006)
  • K. Tidgewell et al.

    Bioorg. Med. Chem. Lett.

    (2004)
  • P.J. Pauwels et al.

    Neuropharmacology

    (2000)
  • A.E. Remmers et al.

    Eur. J. Pharmacol.

    (2000)
  • P.S. Portoghese

    Trends Pharmacol. Sci.

    (1989)
  • A. Coop et al.

    Am. J. Pharm. Educ.

    (2002)
  • T.J. Martin et al.

    J. Pharmacol. Exp. Ther.

    (2001)
  • A.F. Casy et al.

    Opioid Analgesics: Chemistry and Receptors

    (1986)
  • B.L. Roth et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (2002)
  • C.E. Groer et al.

    Mol. Pharmacol.

    (2007)
  • T.A. Munro et al.

    J. Med. Chem.

    (2005)
  • W.W. Harding et al.

    J. Nat. Prod.

    (2006)
  • Cited by (26)

    • A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse

      2022, European Journal of Medicinal Chemistry
      Citation Excerpt :

      As mentioned above, salvinorin A is an interesting non-opiate KOR agonist that has been used as an important prototype for the development of related drug candidates targeting different opioid receptors. In 2007, Prisinzano and coworkers synthesized many salvinorin compounds with modifications at the C1 ketone to explore the effects at this position [79]. They discovered six compounds that showed antagonistic activity on opioid receptors, five of which were antagonists at KOR, MOR, and DOR, and one of which was an antagonist at MOR and DOR, but a partial agonist at KOR.

    • A review of salvinorin analogs and their kappa-opioid receptor activity

      2018, Bioorganic and Medicinal Chemistry Letters
      Citation Excerpt :

      Removal of the C1 ketone in the A ring (52) causes a modest loss (3–6.2-fold) in potency and affinity (4.5-fold), whereas introduction of an H-bond donor as in alcohol 53 results in a steeper loss in affinity (280-fold).38,66 In fact, alcohol 53 was reported in one publication as an antagonist of κ-OR.66 Protecting this alcohol did recover some activity, as in mesylate 54 (60-fold less active than SalA).66

    • Pharmacology and Structure-Activity Relationship of Natural Products With Psychoactive Effects From Salvia divinorum, Mitragyna speciosa, and Ayahuasca

      2017, Studies in Natural Products Chemistry
      Citation Excerpt :

      Another investigation into structural derivatives of SA investigated changes to the ketone functional group in position 1 [112,113]. Interestingly, reduction of the ketone group to a hydroxyl group, substitution with sulfur, or replacement with a double bond led to antagonistic activity at all opioid receptors, although the affinity was significantly reduced with the removal of the electron-rich environment in position 1 [113]. The current structure-activity relationship investigations for SA indicate that the pharmacophore is restrictive and does not allow for significant modifications to increase binding affinity or activity.

    • Semisynthetic neoclerodanes as kappa opioid receptor probes

      2012, Bioorganic and Medicinal Chemistry
    View all citing articles on Scopus
    View full text